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Abstract
Pre-symptomatic (or Preclinical) Alzheimer’s Disease is defined by biomarker evidence of
fibrillar amyloid beta pathology in the absence of clinical symptoms. Clinical trials in this
early phase of disease are challenging due to the slow rate of disease progression as measured
by periodic cognitive performance tests or by transition to a diagnosis of Mild Cognitive
Impairment. In a multisite study, experts provide diagnoses by central chart review without
the benefit of in-person assessment. We use a simulation study to demonstrate that models of
repeated cognitive assessments detect treatment effects more efficiently compared to models
of time-to-progression to an endpoint such as change in diagnosis. Multivariate continuous
data are simulated from a Bayesian joint mixed effects model fit to data from the Alzheimer’s
Disease Neuroimaging Initiative. Simulated progression events are algorithmically derived
from the continuous assessments using a random forest model fit to the same data. We
find that power is approximately doubled with models of repeated continuous outcomes
compared to the time-to-progression analysis. The simulations also demonstrate that a
plausible informative missing data pattern can induce a bias which inflates treatment effects,
yet 5% Type I error is maintained.
Keywords: clinical trial simulations, Alzheimer’s Disease, Cox proportional hazards
model, longitudinal data, mixed model of repeated measures (MMRM), statistical power,
common close design, Bayesian joint mixed effect model
1. Introduction
Pre-symptomatic (or Preclinical) Alzheimer’s Disease (PAD) is defined by evidence of ab-
normal levels of fibrillar amyloid beta in brain as measured by positron emission tomography
(PET) brain scan or cerebrospinal fluid (CSF) assay [1]. Clinical trials have been initiated
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in this early phase of disease with the hope that, as in other diseases, early interventions will
be more successful in slowing progression [2, 3, 4].
In PAD, progression is typically measured by continuous assessments such as the Preclin-
ical Alzheimer’s Cognitive Composite (PACC), a cognitive performance assessment sensitive
to amyloid-related decline [5]. An alternative measure of progression is transition from nor-
mal cognition to Mild Cognitive Impairment (MCI). The diagnosis of MCI is not algorithmic.
It is based on an expert clinician’s subjective impression of clinical tests and interviews with
participants or study partners. In contrast to cancer progression or death, the cognitive di-
agnosis (normal or MCI) can vary from one clinician to the next, or from one study visit to
the next. In a multicenter study, the diagnosis made by a clinician at a trial performance site
may be confirmed by experts centrally based on review of assessments without the benefit
of direct in-person assessment.
Some researchers prefer the inherent clinical meaningfulness of time-to-MCI analysis.
Undoubtedly, for a given subject, a transition from normal cognition to MCI is more clinically
meaningful than a point change in a continuous cognitive performance measure. However,
in a clinical trial, we are still left to determine how large a randomized group difference in
the rate of, or delay in, a clinically meaningful event is itself clinically meaningful.
The typical Alzheimer’s clinical trial assesses cognition at clinic visits conducted every
three or six months. With a continuous outcome, the primary contrast is estimated at
the last scheduled visit, at 4.5 years say. Proponents of time-to-progression argue that the
endpoint allows for a common close design, similar to oncology studies, in which follow-up
can continue until the last subject enrolled reaches the 4.5 year visit. The Cox Proportional
Hazards model [6] admits data collected under such a design. Linear mixed-effects models
can also admit data from a common close design, but assumptions about the mean trend
(e.g. quadratic time trends) are necessary, similar to the proportional hazards assumption.
Some related work has demonstrated the advantages of analyzing continuous outcomes,
when available, over time-to-event outcomes in other contexts. Donohue, et al. [7] reviewed
the literature and provided an analytic demonstration that, under general conditions, a
mixed-effect model comparison of rate of change on a continuous outcome is effectively
always more powerful than an analysis of time-to-threshold. The authors also conducted
simulations based on Alzheimer’s Disease Neuroimaging Initiative (ADNI) MCI subjects
and demonstrated that the marginal linear model and linear mixed models are more robust
and efficient than the Cox model of time from MCI to dementia.
Our goal is to extend our earlier work in the MCI population [7] to the earlier biomarker
defined PAD population. Specifically, we aim to compare the performance of models of
repeated measures of the PACC versus time-to-progression when evaluating treatment effects
in randomized trials, and to assess bias due to informative missingness. We also compare
the common close design and the fixed follow-up design. We apply the Mixed Models of
Repeated Measures (MMRM) [8] for the analysis of change in the PACC score. Constrained
longitudinal data analysis (cLDA) models [9] are also used to model the PACC scores treating
time as a continuous variable. Cox proportional hazards model is applied to time-to-event
endpoint.
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2. Data
ADNI is a prospective observational cohort study, led by Principal Investigator Michael
W. Weiner, MD, which is tracking cognitive, imaging, and biofluid markers of Alzheimer’s in
volunteers diagnosed as cognitively normal (CN), subjective memory concern (SMC), mild
cognitive impairment (MCI) and mild-to-moderate dementia. To simulate both longitudinal
continuous markers and time-to-MCI for a Preclinical AD (PAD) clinical trial, we first model
the disease markers and clinical diagnosis using data from PAD ADNI participants. The
PAD population is defined by a diagnosis of CN or SMC at baseline, and florbetapir PET
standardized uptake value ratio (SUVR) above 1.11 [10] or CSF amyloid beta (Aβ) below
950.6 pg/ml. The CSF threshold of 950.6 pg/ml was selected because it yields the same
proportion of PAD as the 1.11 SUVR threshold. Follow-up observations, including a site
clinician’s diagnosis of CN, MCI, or dementia, are collected every three, six, or 12 months.
For more information on the study design of ADNI, including protocols, see adni.loni.
usc.edu.
Sensitive tests of cognition may show changes in PAD many years before the onset of
functional decline [5, 11]. In this work, we focus on seven cognitive outcomes in the PAD
population, namely:
1. ADAS Delayed Word Recall (ADAS-DWR) [12],
2. Logical Memory Paragraph Recall (LogMem) [13],
3. Trail Making Test Part B (Trails B) [14],
4. Mini-Mental State Examination (MMSE) [15],
5. Category Fluency - Animals,
6. Clinical Dementia Rating - Sum of Boxes (CDRSB) [16] and
7. Functional Assessment Questionnaire (FAQ).
Baseline covariates considered include age and carriage of an apolipoportein E4 (APOEε4)
allele. The PAD population includes a total of N =163 individuals, in which N =39 (23.9%)
were observed to progress to MCI over a median follow-up time of 4.0 years (interquartile
range 2.1 to 5.6 years; maximum 11.5 years). Baseline characteristics of the modeled PAD
cohort are presented in Table 1.
3. Methods
3.1. Joint mixed-effects model for longitudinal data
To a derive a model to simulate plausible data, we first fit a model to observed ADNI
data. We apply a joint (or multivariate) mixed-effects model (JMM) to simultaneous model
continuous longitudinal data for disease markers in the PAD population. The model respects
the within-subject correlation over time and among the battery outcomes.
Suppose we have a set of n subjects followed over a time interval [0, τ). The ith subject
provides a set of longitudinal quantitative measurements {yijk, j = 1, · · · , nik, k = 1, · · · , p}
at time points {tijk, j = 1, · · · , ni, k = 1, · · · , p}. Linear mixed-effects models are com-
monly used to model continuous longitudinal data. The multivariate mixed-effects model is
specified as yijk = x
′
ijkβk + b0ik + b1iktijk + εijk, where βk are fixed-effect regression coef-
ficients, b0ik and b1ik are the subject- and outcome-specific random intercept and slope for
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individual i and outcome k. The random effects are assumed to follow a multivariate Gaus-
sian distribution with mean vector 0 and variance-covariance matrix Σ with dimension 2p,
that is (b0i1, · · · , b0ip, b1i1, · · · , b1ip)′ ∼ N (0,Σ). The model with multivariate random effects
has the advantage of reflecting the dependency within subjects and among outcomes. The
εijk ∼ N (0, σ2k) is a measurement error term, which accounts for outcome-specific variance.
Since the outcomes are in different scales, we transform the raw outcome measures into
a quantile scale ranging from 0 to 1 (least impaired to most severe dementia). Quantiles
are calculated using the empirical cumulative distribution function using weights that are
inversely proportional to the number of observations from each diagnostic category for each
outcome. The quantiles were then transformed by the inverse Gaussian quantile function
resulting an approximate Z-score before submitting to the model. When simulating data
from these models, the simulated Z-scores can then be back transformed to the original
scale, which is integer valued for some outcomes.
Bayesian estimation is performed via Markov Chain Monte Carlo (MCMC) sampling
using the stan mvmer function in R package Rstanarm [17]. Because the stan mvmer function
is limited to a maximum of three outcomes, we have coded our own version allowing up to
twenty outcomes (available from github.com/mcdonohue/rstanarm).
3.2. Random forest algorithm for diagnosis of MCI
In order to simulate a clinician’s diagnosis of MCI or worse impairment, we first use ADNI
data to learn an algorithm to approximate this decision. The random forest algorithm [18]
is an ensemble learning method for classification and regression. It operates by generating
several decision trees and aggregating them. It provides reasonable and easily interpretable
model when a large number of predictors are present in the data and enables applications
with mixed data-types such as continuous and categorical data.
In our application, clinician diagnosis of normal cognition versus MCI or worse impair-
ment is the binary outcome variable, and the seven continuous markers, age and education
are the predictors. The model is fit using the R package randomForest [19]. The fitted
model is then applied to simulated continuous outcomes to predict a clinician’s diagnosis.
3.3. Competing clinical trial models for continuous and time-to-event outcomes in simulation
study
The simulated treatment effect on time-to-progression is modeled by the Cox proportional
hazards model. For the continuous PACC, we consider MMRM and the the constrained
longitudinal data analysis (cLDA) proposed by Liang and Zeger [9]. Like most likelihood-
based approaches for longitudinal data, all three models assume any missing data are missing
at random (MAR).
The PACC is used as the continuous outcome measure for the PAD trials simulation study.
The version of the PACC used in the study is a composite of four assessments: ADAS-DWR,
LogMem, log transformation of Trails B, and MMSE. Each of the four component scores is
first centered by subtracting the baseline sample mean and then divided by the baseline
sample standard deviation of that component, to form standardized Z-scores. These Z-
scores are averaged to form the composite.
The MMRM for treats change from baseline in the PACC score as the outcome and
baseline PACC as a predictor. It treats time as a categorical variable, which allows general
mean trends in each group. MMRM has been extensively used for testing treatment effects
4
at specific time points in clinical trials, since participants are often evaluated at a fixed
and relatively small number of time points [20]. In our simulation study, the within-subject
dependence is modeled by a first-order autoregressive covariance structure.
We also explore models that treat time as a continuous variable. In cLDA, the baseline
outcome is treated as a response variable rather than a covariate, and constrained to have
equal mean at baseline across treatment groups [21, 22]. We explore models with linear or
quadratic time trends for each group.
3.4. Simulation set-up
We conduct a simulation study to evaluate the performance of the competing models
described in Section 3.3. In each of 1000 simulated clinical trials with visits every 6 months
from 0 to 8 years, a total of 1000 and 1500 patients are respectively randomized to either
treatment or placebo in 1:1 ratio. We also assume the proportion of MCI progressors is 24%
(based on ADNI data, as noted above).
For the placebo group, no changes will be made to the JMM fit to ADNI. For the
treatment group, we will impose large (40% improvement on rate of change over the control),
moderate (30% improvement), small (20% improvement) and null (same as the control)
treatment effects on all outcomes. The PACC scores are calculated by taking the average of
the four simulated component Z-scores.
To simulate non-ignorable missing data, three dropout categories are considered: intol-
erability, inefficacy and missing completed at random (MCAR). Participants having intol-
erability or inefficacy drop out from the study immediately after six and twelve months,
respectively. For MCAR, we assume linear attrition rate of 5% per year for both the treat-
ment and placebo groups. The simulated dropout rates are:
- Treatment group:
- Null: inefficacy (15%), intolerability (10%), MCAR (5%/year attrition rate);
- Alternative: inefficacy (8%), intolerability (10%), MCAR (5%/year attrition rate);
- Placebo group: inefficacy (15%), MCAR (5%/year attrition rate).
In order to assess bias due to missing data, we simulate complete data for every subject.
The complete data is appropriately censored for the analysis of “observed” data, and left
uncensored for analysis of the “complete” data. Completers and MCAR dropouts are as-
sumed to have the same longitudinal mean profile within each treatment arm. Dropouts
due to intolerability are simulated to have the expected benefit, on average, until dropout,
followed by an “unobserved” benefit that is diminished by a factor of 15%. Dropouts due to
inefficacy are simulated to have no benefit.
The four competing clinical trial models are MMRM, cLDA1 (linear) and cLDA2 (quadratic)
for continuous PACC scores; and Cox for time-to-progression, with two baseline covariates:
age at baseline and carriage of the APOEε4allele. The Cox model will use all data observed
out to 8 years until the last subject reaches the final scheduled visit under the common close
design. We assume a linear enrollment rate such that enrollment is completed in 4 years and
about half the subjects contribute “extra” common close follow-up in the 4.5 to 8 year range
to the Cox model. The MMRM, cLDA1 and cLDA2 will only use data up to last scheduled
visit, i.e., from 0 to 4.5 years.
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We focus on “treatment policy” estimands of interest. The estimand will be the difference
between randomized groups in the intention-to-treat population in terms of either: (I) Rate
(hazard ratio) of progression to MCI/Dementia (Cox); (II) Group difference in PACC at final
study time point (MMRM and cLDA1); or (III) Area between mean PACC curves (cLDA2).
We show how to carry out the hypothesis test of case (III) in the Appendix. Let Yijk denote
the simulated PACC scores for subject i randomized to group j at time point k, where
i = 1, · · · , nj, j = D,P and k = 1, · · · , T . And k = 0 represents the baseline time point, D
is the treatment group and P is the placebo group. If the estimand of interest is the change
from baseline at time T , i.e., YijT − Yij0. The object is to estimate the between-treatment
difference δ = µP − µD, where µj = E (YijT − Yij0). A two-tailed test H0 : δ = 0 versus
H1 : δ 6= 0 is carried out to evaluate whether treatment is different from placebo.
For each simulated dataset, we apply all four competing models to calculate point esti-
mates of δ using the observed data (i.e., δobs) and the complete data (i.e., δcomp). For each
model, “bias” is calculated as the median of the 1000 point estimates of δobs minus δcomp;
“bias in percent” is computed as the median of the 1000 points estimates of δobs minus δcomp
and then divided by δcomp. The interquartiles Q1 and Q3 are also summarized.
In a real clinical trial, the endpoint is measured for completers but is missing for those
who either drop out from the study either due to inefficacy or intolerability or those who
remain in the study after initiating rescue medication. Mehrotra, et al. [23] discussed that
the commonly used MMRM with the embedded MAR assumption can deliver an exaggerated
estimate of the aforementioned estimand of interest, in favor of the drug. This happens, in
part, due to implicit imputation of an overly optimistic mean for dropouts in the treatment
group. To remedy this, they proposed a formula-based two-step approach by treating the
true endpoint distribution for treatment group as a mixture of distributions (one each for
the completers and dropouts) rather than a single distribution. Their approach reduces
the bias associated with the traditional MMRM while maintaining power. To increase the
precision in estimating δ, we apply their method to MMRM, cLDA1 and cLDA2 models in
the simulation study.
4. Results
4.1. JMM and random forest fit to ADNI data
We fit a JMM for PAD participants who were observed to progress to MCI and a separate
JMM for those who did not progress. Seven outcome measures described in Section 2 are
included in the model. Fixed effect covariates for each outcome include age at baseline and
carriage of the APOEε4allele. Three parallel Markov chains are run for 4000 iterations and
the first 2000 warm-up iterations are discarded. Every fourth value of the remaining part
of each chain is stored to reduce correlation, yielding a total of 1500 samples for posterior
analysis. Table 2 shows the posterior means and 95% credible intervals of the covariate-effect
parameters. Figure 1 shows the subject-level observations and predictions according to time
in years of the seven markers for all individuals, in which the blue and red lines are the
curves using the LOESS smoother. The bottom panel shows that the predictions provide
reasonable trends of the observations. The posterior estimates from JMM will be later used
as the true parameter values to simulate the panel of continuous markers.
For the random forest, 500 trees are fitted and the number of variables selected at each
split is 3. The node impurity of each tree is measured by the Gini index. The results
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show that CDRSB, LogMem and FAQ are three most important outcomes for determining
the diagnosis of MCI. The model has a 6.19% out-of-bag error rate and 93.81% out-of-
bag accuracy rate. Using the fitted random forest, the simulated cognitive status can be
obtained from the simulated continuous markers. Figure 2 shows the Kaplan-Meier estimated
progression rate of the ADNI-PAD population (black solid line) along with the progression
rate from one large simulated placebo group (red dots). The simulated progression yields
closer concordance with the Kaplan-Meier estimates at the earlier stage. Although we observe
discrepancies between the two lines in the middle and the right tail, the red line still lies
within the 95% confidence intervals. Both the subject-level trajectories and the progression
rate illustrate that the simulated data plausibly mimics the observed data.
4.2. Simulation results
Figure 3 shows the results of one simulated clinical trial with a 20% treatment effect and
sample size n = 1000. The figure illustrates the group trends obtained by fitting the four
different models.
Simulated power and Type I error are summarized in Table 3. Under the null hypothesis
(no treatment effect), the MMRM exhibits smaller than expected Type I error (about 2%),
whereas the other models are closer to the expect 5% error rate. The Cox model consistently
exhibits the weakest power of the four models. MMRM has the next best performance,
followed by the quadratic (cLDA2) and linear (cLDA1) models. For example, with a trial
of size N =1,000 subjects of drug with a 30% treatment effect, the simulated power is 33%
for Cox, 79% for MMRM, 86% for cLDA2, and 96% for cLDA1. In comparing analysis of
complete versus observed data, it seems the missing data does not increase Type I error, but
it does inflate power. This suggests the bias is only an issue with an effective drug, in which
case the effectiveness might appear inflated. Figure 4 shows the powers in all scenarios.
Tables 4 and 5 further examine the bias induced by the missing data pattern. The
tables summarize the median and interquartile ranges (Q1,Q3) of the bias on the PACC
scale (Tables 4) and as a percent of effect seen in complete data (5). The Cox model seems
to have smaller bias with 20% treatment effect, but as the treatment grows, the bias is
comparable for all models. The method proposed by Mehrotra, et al. [23] successfully
shrinks the magnitude of bias, e.g. from 27% in favor of treatment to -4.4% in favor of
placebo for MMRM with 20% treatment effect. The method appears to overcorrect the bias
in favor of placebo in these simulations.
5. Discussion
We use Bayesian joint mixed effects models fit using ADNI data to simulate correlated
longitudinal data that might plausibly arise in a PAD clinical trial. We used a random forest
algorithm, also fit using ADNI, to algorithmically diagnose MCI in the simulated data so
that we could compare models of the PACC to the Cox model of time-to-progression. The
models of PACC consistently provide at least twice the power of the Cox model even when
the Cox model has the benefit of considerably more follow-up under a common close design.
Given this inefficiency, the time-to-progression analysis should be avoided in PAD.
Some might still argue that the clinical meaningfulness of the time-to-progression is worth
the cost of a larger, longer trial. However, given that the random forest provided a purely
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algorithmic diagnosis with 93.81% out-of-bag accuracy suggests that there is minimal addi-
tional value in the diagnosis. And again, while the progression outcome is more qualitative
than the PACC on the subject level, the group level result is still quantitative (e.g. a hazard
ratio) and requires additional interpretation to assign clinical meaning.
One might also argued that clinical diagnosis cannot be adequately modelled algorithmi-
cally using trial data. That is, clinical assessment and diagnosis by a trial site clinician may
consider information not captured by trial measures. But the cognitive, clinical and func-
tional assessments are designed to capture the relevant information, and clinicians generally
rely on similar information obtained through less structured assessments. It seems question-
able that a site clinician will gain much reliable information beyond the assessments; indeed,
this is the justification for central expert panel adjudication of site diagnoses.
The Bayesian joint models are well-suited to simulating plausible panels of correlated
longitudinal data necessary to compare clinical trial designs. This approach could be useful
in many other contexts where one is interested in a fair comparison of different outcome
measures, different combinations of correlated outcomes, or different models of treatment
effect. Simulations which ignore the correlations among important outcomes will likely not
provide reliable comparisons.
All of the models considered were susceptible to bias induced by a plausible missing
data pattern. However, this bias seemed to only affect scenarios with an effective treatment
and did not inflate Type I error under the null hypothesis. The Mehrotra method shows
promise in correcting this bias, but it might overcorrect in favor of placebo, and it would be
impossible to detect this overcorrection in practice. Given that Type I error is not inflated,
we are inclined to suggest no change to the status quo approach in which the primary analysis
is based on likelihood-based methods which are robust to MAR, and applying appropriate
MNAR sensitivity analyses such as the delta method[24].
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Appendix
For cLDA model with quadratic time effects, we can write the part of fixed effects as
y = β0 + β1t+ β2t · active + β3t2 + β4t2 · active
The area between the curves of active group and placebo group is
Strt-pb =
∫ tT
t0
{
β0 + (β1 + β2) t+ (β3 + β4) t
2
}
dt−
∫ tT
t0
{
β0 + β1t+ β3t
2
}
dt
=
(
1
2
β2t
2 +
1
3
β4t
3
)∣∣∣∣t=tT
t=t0
The null hypothesis is H0: Strt−pb = 0. We use the R package glht to carry out the
hypothesis test.
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Table 1: Descriptive statistics by baseline diagnosis, normal cognition (NC) and subjective memory concern
(SMC) for the Preclinical Alzheimer’s Disease population in the Alzheimer’s Disease Neuroimaging Initiative:
Count (%) or mean (SD).
NC SMC Total
Variable (N = 120) (N = 43) (N = 163)
Age 75.21 (5.83) 72.77 (5.78) 74.57 (5.90)
APOEε4 alleles 0 52 (43%) 23 (53%) 75 (46%)
≥1 111 (57%) 140 (47%) 88 (54%)
ADAS Delayed Word Recall 2.96 ( 1.79) 3.00 ( 2.08) 2.97 ( 1.86)
Logical Memory - Delayed Recall 13.11 ( 3.15) 12.63 ( 3.19) 12.98 ( 3.16)
Trails B 93.40 (48.90) 89.10 (32.00) 92.30 (45.00)
MMSE 29.11 ( 1.13) 29.09 ( 0.89) 29.10 ( 1.07)
Category Fluency (Animals) 20.72 ( 5.32) 19.72 ( 5.60) 20.45 ( 5.40)
CDR-SB 0 111 (92%) 36 (84%) 147 (90%)
0.5 8 ( 7%) 7 (16%) 15 ( 9%)
1 1 ( 1%) 0 ( 0%) 1 ( 1%)
FAQ 0 108 (90%) 32 (74%) 140 (86%)
1 7 ( 6%) 8 (19%) 15 ( 9%)
2 2 ( 2%) 0 ( 0%) 2 ( 1%)
3 2 ( 2%) 3 ( 7%) 5 ( 3%)
5 1 ( 1%) 0 ( 0%) 1 ( 1%)
11
Table 2: Posterior estimates (means and 95% credible intervals) of the fixed effect covariates for the joint
mixed effect model fit to seven outcomes for stable and MCI progressor subpopulations.
Progressor (N = 39) Stable (N = 124)
Parameter Mean 95% CI Mean 95% CI
ADAS Delayed Word Recall
Intercept -8.244 (−15.39,−1.451) -4.913 (−7.755,−2.003)
Year 0.330 (0.189, 0.464) 0.064 (0.021, 0.108)
Age 0.110 (0.021, 0.201) 0.062 (0.023, 0.100)
APOEε4 0.572 (−0.319, 1.437) 0.218 (−0.247, 0.670)
Logical Memory Paragraph Recall
Intercept -6.897 (−15.425, 0.905) -1.840 (−4.983, 1.350)
Year 0.261 (0.136, 0.395) 0.033 (−0.084, 0.016)
Age 0.096 (−0.005, 0.206) 0.020 (−0.023, 0.062)
APOEε4 0.039 (−0.959, 1.099) 0.465 (−0.044, 0.985)
Trails B
Intercept -9.458 (−14.898,−3.918) -6.364 (−9.020,−3.792)
Year 0.353 (0.252, 0.445) 0.022 (−0.028, 0.073)
Age 0.124 (0.051, 0.193) 0.084 (0.050, 0.119)
APOEε4 0.141 (−0.540, 0.858) 0.622 (0.187, 1.087)
Mini-Mental State Examination
Intercept 0.852 (−191.780, 185.973) -1.385 (−75.020, 72.568)
Year 0.009 (−3.918, 4.011) 0.022 (−2.590, 2.698)
Age 0.007 (−2.432, 2.436) 0.020 (−0.903, 0.944)
APOEε4 0.040 (−1.116, 11.346) 0.115 (−5.683, 5.900)
Category Fluency - Animals
Intercept 1.430 (−127.590, 130.195) 0.942 (−96.958, 98.426)
Year 0.047 (−2.910, 2.786) 0.025 (−3.399, 3.798)
Age -0.009 (−1.658, 1.606) -0.011 (−1.224, 1.211)
APOEε4 0.036 (−8.234, 8.775) -0.118 (−7.911, 7.920)
Clinical Dementia Rating - Sum of Boxes
Intercept -6.537 (−364.967, 344.177) 1.094 (−82.421, 76.732)
Year 0.082 (−7.263, 6.390) 0.006 (−2.853, 2.947)
Age 0.081 (−4.230, 4.517) -0.011 (−1.006, 1.027)
APOEε4 -0.224 (−20.697, 19.566) 0.117 (−5.925, 6.358)
Functional Assessment Questionnaire
Intercept 3.458 (−380.068, 367.151) 0.261 (−32.960, 32.991)
Year 0.023 (−7.838, 7.140) 0.0007 (−1.1420, 1.1710)
Age -0.002 (−4.487, 4.718) -0.003 (−0.410, 0.449)
APOEε4 0.343 (−22.127, 22.506) 0.014 (−2.667, 2.525)
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Table 3: Power and Type I error from 1000 simulated clinical trials. The rows with 0% treatment effect
simulate the Type I error, which we expect to be near 5%.
Sample Observed data Completed data
size Treatment MMRM cLDA1 cLDA2 CoxPH MMRM cLDA1 cLDA2 CoxPH
1000
0% 0.021 0.051 0.053 0.040 0.027 0.049 0.057 0.046
20% 0.404 0.702 0.502 0.188 0.298 0.564 0.402 0.159
30% 0.794 0.957 0.856 0.322 0.666 0.897 0.751 0.274
40% 0.970 0.999 0.981 0.496 0.907 0.990 0.947 0.425
1500
0% 0.024 0.042 0.054 0.058 0.014 0.048 0.051 0.055
20% 0.560 0.843 0.660 0.261 0.454 0.722 0.550 0.232
30% 0.927 0.996 0.954 0.452 0.847 0.973 0.907 0.392
40% 1.000 1.000 1.000 0.653 0.994 1.000 0.996 0.573
Table 4: Bias of the treatment effect due to missingness.
Sample 20% 30% 40%
size Analysis Method Median (Q1,Q3) Median (Q1,Q3) Median (Q1,Q3)
1000
MMRM 0.018 (0.006, 0.031) 0.028 (0.015, 0.040) 0.037 (0.024, 0.049)
cLDA1 0.019 (0.009, 0.029) 0.028 (0.018, 0.038) 0.038 (0.028, 0.048)
cLDA2 0.038 (0.011, 0.065) 0.058 (0.030, 0.084) 0.077 (0.050, 0.104)
CoxPH -0.033 (−0.074, 0.010) -0.045 (−0.086,−0.001) -0.059 (−0.102,−0.017)
MMRM-Mehrotra -0.001 (−0.015, 0.012) -0.002 (−0.016, 0.011) -0.003 (−0.017, 0.010)
cLDA1-Mehrotra -0.001 (−0.011, 0.008) -0.001 (−0.012, 0.007) -0.003 (−0.012, 0.007)
cLDA2-Mehrotra -0.006 (−0.034, 0.022) -0.010 (−0.038, 0.018) -0.014 (−0.042, 0.014)
1500
MMRM 0.018 (0.006, 0.028) 0.027 (0.016, 0.037) 0.036 (0.025, 0.047)
cLDA1 0.018 (0.010, 0.026) 0.027 (0.019, 0.036) 0.037 (0.028, 0.045)
cLDA2 0.037 (0.013, 0.061) 0.056 (0.032, 0.080) 0.075 (0.052, 0.099)
CoxPH -0.028 (−0.064, 0.005) -0.042 (−0.076,−0.009) -0.055 (−0.090,−0.021)
MMRM-Mehrotra -0.002 (−0.012, 0.009) -0.003 (−0.013, 0.008) -0.004 (−0.015, 0.007)
cLDA1-Mehrotra -0.001 (−0.009, 0.006) -0.002 (−0.010, 0.005) -0.003 (−0.011, 0.004)
cLDA2-Mehrotra -0.008 (−0.028, 0.015) -0.012 (−0.032, 0.011) -0.016 (−0.035, 0.007)
Table 5: Bias in percent (%) of the treatment effect due to missingness based on 1000 simulated trials for
the given sample size, treatment effect, and analysis method.
Sample 20% 30% 40%
size Analysis Method Median (Q1,Q3) Median (Q1,Q3) Median (Q1,Q3)
1000
MMRM 27.1 (7.0, 52.3) 29.9 (16.3, 46.8) 29.6 (19.4, 42.3)
cLDA1 29.6 (12.4, 51.9) 29.8 (18.9, 43.7) 29.7 (21.4, 39.7)
cLDA2 24.5 (5.5, 50.2) 26.5 (13.7, 42.6) 26.2 (16.5, 37.9)
CoxPH 17.4 (−16.1, 55.0) 22.2 (−4.5, 52.7) 25.5 (5.2, 50.4)
MMRM-Mehrotra -4.4 (−23.2, 20.6) -2.9 (−15.9, 13.3) -2.8 (−12.7, 8.6)
cLDA1-Mehrotra -1.7 (−16.2, 15.4) -1.7 (−11.3, 9.1) -2.0 (−9.2, 5.7)
cLDA2-Mehrotra -6.0 (−21.2, 15.9) -4.5 (−15.5, 9.4) -4.7 (−13.0, 5.2)
1500
MMRM 27.5 (9.7, 52.8) 28.2 (16.6, 43.3) 28.3 (19.6, 39.3)
cLDA1 29.1 (15.7, 48.4) 29.2 (19.9, 40.9) 29.3 (22.2, 37.8)
cLDA2 24.8 (8.8, 45.6) 25.4 (15.2, 38.2) 25.5 (17.8, 34.6)
CoxPH 18.0 (−8.2, 46.9) 22.7 (3, 46.3) 24.3 (8.6, 44.6)
MMRM-Mehrotra -3.0 (−19.4, 17.6) -3.0 (−13.8, 9.7) -3.1 (−11.2, 6.2)
cLDA1-Mehrotra -2.1 (−13.5, 11.4) -2.3 (−9.8, 5.7) -2.4 (−7.9, 3.5)
cLDA2-Mehrotra -6.1 (−18.8, 12.7) -5.5 (−13.9, 5.7) -5.5 (−11.5, 2.8)
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Figure 1: Observed (upper panel) and predicted (lower panel) longitudinal profiles of the seven markers for
all individuals. Bold lines are LOESS smoothes.
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Figure 2: Kaplan-Meier estimated rate of progression to MCI or Dementia.
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Figure 3: Results of one simulated clinical trial with 20% treatment effect from (a) analysis of change
from baseline using a categorical time MMRM of the PACC; (b) a cLDA model of PACC with linear time
trends; (c) a cLDA model of PACC with quadratic time effects; and (d) Kaplan-Meier curves comparing the
time-to-progression to Mild Cognitive Impairment or dementia for the two groups.
15
Sample size: 1000 Sample size: 1500
0 20% 30% 40% 0 20% 30% 40%
0.00
0.25
0.50
0.75
1.00
Treatment
P
o
w
e
r
MMRM
cLDA−linear
cLDA−quadratic
CoxPH
Observed data
Completed data
Figure 4: Statistical power for the MMRM, cLDA and Cox proportional hazards model for treatment effects
0% (Type I error), 20%, 30% and 40% for sample sizes of n=1000 (left panel) and n=1500 (right panel). Solid
lines indicate power estimates for data observed after simulated non-ignorable missingness; and dashed lines
indicate power that would be achieved with complete data (including observations that would be unobserved
in reality). The observed data shows greater power with fewer observations because the non-ignorable
missingness induces a bias in favor of the treatment.
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